We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

49 hedge funds and large institutions have $8.3M invested in Galectin Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

0.38% less ownership

Funds ownership: 11.48% → 11.1% (-0.38%)

6% less funds holding

Funds holding: 52 → 49 (-3)

15% less capital invested

Capital invested by funds: $9.77M → $8.3M (-$1.47M)

21% less call options, than puts

Call options by funds: $523K | Put options by funds: $659K

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
49
Holders Change
-3
Holders Change %
-5.77%
% of All Funds
1.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
9
Closed
8
Calls
$523K
Puts
$659K
Net Calls
-$136K
Net Calls Change
-$330K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$165K
2
AG
Advisor Group
Arizona
+$71K
3
Simplex Trading
Simplex Trading
Illinois
+$56.8K
4
Group One Trading
Group One Trading
Illinois
+$45.7K
5
MML Investors Services
MML Investors Services
Massachusetts
+$22.6K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$112K
2
DADC
D.A. Davidson & Co
Montana
-$94.2K
3
BIP
Brandes Investment Partners
California
-$70K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$40.7K
5
Millennium Management
Millennium Management
New York
-$27K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAN
26
Cetera Advisor Networks
California
$34K – – –
LWAC
27
Laurel Wealth Advisors (California)
California
$34K – – –
Goldman Sachs
28
Goldman Sachs
New York
$30K -$6.05K -3,055 -18%
State Street
29
State Street
Massachusetts
$26K – – –
GC
30
Guggenheim Capital
Illinois
$25K -$42 -21 -0.2%
Wells Fargo
31
Wells Fargo
California
$25K – – –
MML Investors Services
32
MML Investors Services
Massachusetts
$24K +$22.6K +11,391 New
DAS
33
Dynamic Advisor Solutions
Arizona
$21K – – –
Bank of America
34
Bank of America
North Carolina
$16K +$3.67K +1,853 +32%
UBS Group
35
UBS Group
Switzerland
$14K +$8.38K +4,230 +175%
IA
36
IFP Advisors
Florida
$13K – – –
Thrivent Financial for Lutherans
37
Thrivent Financial for Lutherans
Minnesota
$13K +$11.9K +6,000 New
IWM
38
IHT Wealth Management
Illinois
$10K – – –
SEI Investments
39
SEI Investments
Pennsylvania
$8K – – –
CG
40
Cutler Group
California
$4K – – –
LTFS
41
Ladenburg Thalmann Financial Services
Florida
$4K +$3.96K +2,000 New
NFG
42
Next Financial Group
Texas
$3K – – –
PRS
43
Pinkerton Retirement Specialists
Idaho
$2K – – –
RAM
44
Riggs Asset Management
Pennsylvania
$2K – – –
TWA
45
TCI Wealth Advisors
Arizona
$1K – – –
RE
46
RBC Europe
United Kingdom
$86 +$79 +40 New
ARTA
47
A.R.T. Advisors
New York
– -$112K -45,843 Closed
BIP
48
Brandes Investment Partners
California
– -$70K -28,500 Closed
Citadel Advisors
49
Citadel Advisors
Florida
– -$26.4K -13,300 Closed
Millennium Management
50
Millennium Management
New York
– -$27K -11,000 Closed
1
2
3

GALT Hedge Fund Activity: Q3 2017 in Review

49 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2017, worth a combined $8.3M — down 15% from $9.77M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GALT and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 9 added.

The largest buyer was Susquehanna International Group, adding an estimated $165K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $112K sold.

  • 49 institutional investors held Galectin Therapeutics (GALT) as of Q3 2017, down from 52 in Q2 2017.
  • Funds reported $8.3M of Galectin Therapeutics stock for Q3 2017, down 15% quarter-over-quarter.
  • 6 funds opened new Galectin Therapeutics positions in Q3 2017 and 8 closed out, a net change of -2 holders.
  • The largest Galectin Therapeutics buyer in Q3 2017 was Susquehanna International Group, an estimated $165K added.
  • The largest Galectin Therapeutics seller in Q3 2017 was A.R.T. Advisors, an estimated $112K sold.

Based on aggregated 13F filings for Q3 2017.